LAMA2 Payload Integration for Mutation-Independent Gene Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for laminin-α2 chain-deficient congenital muscular dystrophy (LAMA2 MD) are limited by cargo size constraints and lack universality, as existing vectors like AAV and lentiviral vectors cannot accommodate the large 9.3 kb LAMA2 gene, and methods like CRISPR/Cas9 are inefficient for integrating large transgenes or require continuous expression.
Innovation Solution
A fusion protein comprising a site-specific DNA-binding protein, such as Cas9, fused to a hyperactive PiggyBac transposase, is used to integrate a full-length LAMA2 transgene into a specific site within the genome, enabling efficient and universal gene replacement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV or lentiviral vectors are used for gene delivery, then delivery efficiency is improved, but cargo capacity is limited and cannot accommodate the 9.3 kb LAMA2 gene
Solution Approach 1:
The patent combines CRISPR/Cas9 genome editing system with PiggyBac transposase system to create a dual-function platform. The Cas9 protein creates targeted double-strand breaks at specific genomic loci, while the PiggyBac transposase integrates the large LAMA2 transgene (9.3 kb) into the Cas9-cut site. This merging of two different molecular mechanisms enables both high delivery efficiency and large cargo capacity that neither system could achieve alone.
Solution Approach 2:
The patent uses the Cas9-induced double-strand break as an intermediary mechanism to facilitate transposase-mediated integration. The Cas9 system serves as a mediator that prepares the genomic target site by creating a controlled break, which then enhances the efficiency of PiggyBac transposase integration. This intermediary step allows precise targeting while accommodating large transgene cargo.
2Measurement precision
If CRISPR/Cas9 is used to correct LAMA2 mutations, then mutation-specific correction is achieved, but the approach is not universal for all patients with different mutations
Solution Approach 1:
The patent segments the gene therapy approach into two independent components: (1) the Cas9 guide RNA that can be customized to target any specific LAMA2 mutation, and (2) the PiggyBac transposase that handles the actual transgene integration. This segmentation allows the guide RNA to be easily redesigned for different mutations while the integration mechanism remains universal, thus achieving both precision and versatility.
Solution Approach 2:
The PiggyBac transposase system serves as a universal integration platform that can accommodate any LAMA2 transgene sequence regardless of the specific mutation being corrected. Combined with the programmable nature of CRISPR/Cas9 guide RNAs, this creates a multi-functional system that can treat all patients with LAMA2 MD regardless of their specific mutation type.
3Measurement precision
If HDR pathway is used for gene correction, then precise mutation correction is possible, but integration efficiency of large transgenes is extremely low
Solution Approach 1:
The patent replaces the HDR (Homology-Directed Repair) mechanical system with a transposase-based integration system. Instead of relying on HDR to insert the transgene during DNA repair, the patent uses PiggyBac transposase which catalyzes direct cut-and-paste integration of the transgene into the Cas9-cut site. This substitution dramatically improves integration efficiency while maintaining precision through Cas9-targeted site selection.
Solution Approach 2:
The patent changes the fundamental parameter of integration mechanism from HDR-dependent to transposase-dependent. This parameter change transforms the integration process from a low-efficiency homology-based repair pathway to a high-efficiency enzyme-catalyzed transposition pathway, achieving both precise targeting (via Cas9) and high integration efficiency (via PiggyBac).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the permanent integration of a large LAMA2 expression cassette, compatible with various gene delivery technologies, offering a promising therapeutic strategy for LAMA2 MD that is not limited to specific mutations.
Implementation Method 1
a fusion protein comprising a site-specific DNA-binding protein, such as Cas9, fused to a transposase to integrate a full-length LAMA2 transgene into a specific site within the genome
Implementation Method 2
a site-specific DNA-binding protein, such as Cas9, fused to a transposase
Data Source
AI summary
The present invention relates to a composition comprising:a) a first protein comprising or consisting of a site-specific DNA binding protein capable of binding and cleaving a target nucleic acid sequence; or a nucleic acid construct encoding said first protein;b) a second protein comprising or consisting of a transposase; or a nucleic acid construct encoding said second protein; andc) a nucleic acid construct comprising a transgene encoding laminin-α2 protein, or a functional variant or fragment thereof.It also relates to the therapeutic use of this composition, to integrate a LAMA2 transgene into a specific site within the genome of a cell, in particular for the treatment of congenital muscular dystrophy.